International journal of pharmaceutics
Cure8 research brief
Why This Matters
The study describes a new oral delivery system designed to improve colon targeting and anti-inflammatory activity of celastrol, which could eventually lead to better drug options for ulcerative colitis if advanced to human trials.
It’s early-stage research but points to strategies (mucoadhesive hydrogels, plant-derived nanoparticle carriers) that may overcome common barriers to delivering drugs to the colon.
Who Should Pay Attention
Researchers, clinicians, and patients interested in emerging drug-delivery technologies for ulcerative colitis and investigators of natural-product therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a laboratory and preclinical animal study of a novel delivery system, not a clinical trial. The work focuses on improving how celastrol reaches and acts in the colon by combining plant-derived nanoparticle carriers (from ginger) with a mucoadhesive hydrogel.
Reported benefits in the abstract include better colon targeting, longer retention, enhanced cellular uptake, and multiple anti-inflammatory effects in model systems. If you are following IBD research, note that the findings are promising early-stage data about a delivery method rather than evidence that celastrol is safe or effective in people with UC.
No human safety or efficacy data are provided in the abstract.
Keep In Mind
This is preclinical laboratory and animal-model research reported in an abstract; it does not include human clinical data. Promising preclinical findings often do not translate to approved human treatments without further testing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational journal of pharmaceutics
AuthorsNuannuan Li, Ye Jin, Yating Zhao +5 more
InstitutionDepartment Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine, Yantai, Shandong 264100, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 7, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Quaternized chitosan-based double-network hydrogel for oral precise delivery of Sinapic acid in ulcerative colitis therapy.
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
A natural product-based pH-responsive hydrogel nanoplatform for ulcerative colitis therapy via synchronous regulation of immune microenvironment and intestinal barrier.
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...